Patients were stratified according to the type of therapy , and randomized in a ratio of 2:1 to either oral ciprofloxacin 500 mg BID , or a combination of oral neomycin 250 mg QID , polymyxin-B 100 mg QID , and oral nalidixic acid 1,000 mg BID .
